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nomenclature
pp  Patient/population specific solution  
NMR Nuclear magnetic resonance
PET Positron emission tomography
CT  Computer tomography
MS  Mass spectroscopy
GC  Gas chromatography
LC  Liquid chromatography
CE  Capillary electrophoresis
iTRAQ Isobaric tags for relative and absolute   
  quantitation
ICAT	 Isotope-coded	affinity	tag
2DE 2 Dimensional gel electrophoresis
1. PersPective
Stem cell  is a clonal, self-renewing entity that is multipotent 
and thus can generate several differentiated cell type 
(describing cellular attributes only)1. Increasing understanding 
of molecular mechanisms governing their potential can help 
in better understanding and remedy for health problems 
such as neurodegenerative diseases, heart ailments, cancers 
and radiation injury etc. Omics analysis of SC has allowed 
distinguishing	 the	 major	 features	 that	 define	 a	 cell	 as	 SC	
and,	 identification	 of	 its	 stemness,	 differentiation	 and	 tissue	
based	 niche	 regulators.	Omics	 data	 include	 quantification	 of	
mRNA transcripts levels (transcriptome), protein abundance 
(proteome),	 metabolic	 fluxes	 (fluxome),	 intracellular	 and	
extracellular	 metabolites	 concentration	 (metabolome)	 and	
information on protein-protein and protein-DNA interactions 
(interactome).	 To	 efficiently	 extract	 relevant	 biological	
insight from vast amount of data generated, appropriate and 
goal-dependent tools are necessary2.	 In	 order	 to	 extrapolate	
the information stored in omics, drugs and disease database, 
a new tool is required which could integrate all the available 
and evolving information and suggests us an optimal solution 
to a problem (Fig. 1). This would help us in translating the 
ever-increasing biological information about SC from bench-
to-bedside.
At present there are many tools viz. DvD4, MeSH5, 
connectivity map6, Metacore7, etc., which could integrate few 
of the databases and could query the databases on the basis 
of user input. Even a database (StemBase)8 has been created, 
specifically,	 to	 facilitate	 the	 discovery	 of	 gene’s	 function	
relevant to SC control and differentiation. Nevertheless, these 
tools lack capability to integrate all the databases to generate 
a possible solution. The basic idea is to query the available 
repositories	 for	 the	 identification	 of	 SC	 specific	 biomarkers	
under various milieu and novel drug targets for their fates 
regulation. This will facilitate repurposing of known chemical/ 
drug like compounds/ clinically used drugs, for which most 
of the in vitro data, in vivo data and clinical data is available. 
The	 predicted	 candidate	 molecules	 from	 this	 tool	 may	 find	
applications in genome based clinical trials, population studies, 
outcome research and in health care system9. 
1.1 Proposed tool capability
This system will be able to retrieve available data, query 
it,	and	generate	signature	profiles	and	interaction	network	from	
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the	 databases	 for	 a	 given	 instance.	For	 example,	 if	 a	 person	
with disease/ dysfunction/ injury approaches to a clinic, this 
tool should be able to give prognosis (survival analysis) on 
the basis of genomics/ proteomics biomarkers spotted on 
a biosensor chips. The tool could also predict the cause of 
malfunction {(mutations from Genomics and Single Nucleotide 
Polymorphisms (SNPs)} and the protein interactions (Proteome 
and	Interactome)	being	affected	(Fig.	2).	For	this,	individual’s	
clinical data during the course of ageing (from childhood 
to old age) could be stored temporally in a repository as in 
vogue practice of stem cell banking for futuristic applications. 
This information will be vital in case of emergent situation, 
without wasting time on lengthy diagnostic procedures. 
However	on	the	flip	side,	commercialisation	of	this	repository	
by	 private	firms	will	make	 it	 exclusive	 for	 those	who	 could	
afford	this.	The	identification	of	signature	model	deduced	from	
this information would likely to give cues to the underlying 
molecular mechanism. These pathways may be tweaked in SC 
using available/ repurposed drugs for regenerating the affected 
tissue. It would also include analysis of new metabolites 
generated due to these pathologies (Metabolomics), the 
survival chances (Disease bank) and the drugs available (Drug 
bank) for this patient. In addition, descendents of the patients 
could be counselled for their chances of inheriting similar 
phenotype and precautions to be taken for mitigating it. The 
predicted	signature	would	also	find	utility	in	in vitro to guide 
a tissue/organs generation for tissue engineering and increased 
transplantation	 efficiency	 using	 repurposed-drug-primed	 SC.	
The big data analysis based tissue engineering will be a major 
turn in the conceptual approach to reconstruction of tissues and 
organs. In addition, advances in SC biology using multidata 
analysis would make it possible to engineer tissues which were 
otherwise not amenable to reconstruction.
In totality, hitherto, this type of tool is unavailable 
however endeavour to achieve this has been initiated in the 
form of Omic space10. It is a coordinate based integration and 
analysis of genomic phenome interactions. It is available on a 
public server at http://omicspace.riken.jp (known as PosMed 
or Positional Medicine). It ranks genes, metabolites, diseases 
and	drugs	based	on	the	statistical	significance	of	associations	
which are connected through biological databases such as 
MEDLINE,	 OMIM,	 pathway,	 coexpressions,	 molecular	
interactions and ontology terms (Fig. 3(a), 3(b)). 
Nevertheless, it is not capable of providing a possible 
solution; it only suggests a list of interactions which are 
needed to be mined manually. In the absence of availability 
of proposed tool, individual databases and an array of analysis 
tools	may	be	employed	to	achieve	desired	output,	for	example,	
to get genes, disease, drugs, metabolites and protein interaction 
(Table 1). The list of databases and analysis tools would keep on 
increasing along with a new tool employed for a new analysis. 
And	results	obtained	would	be	very	difficult	to	understand	and	
integrate from various tools; this warrants need of a single tool 
which could parse data from multiple databases. 
A	 central	 database	 exchanging	 information	 with	 the	
proposed tool might also result in better understanding of 
immune compatibility and enhanced methods for matching 
patient to donor. Nonetheless, this would need to comply with 
institutional review board (IRB) protocol and may include 
creation of stem cell standards like minimum information 
about	stem	cell	experiments	(MIASCE)12 similar to minimum 
information	 about	 a	 microarray	 experiment	 (MIAME)	
Figure 1. boxes (nodes) indicating the data available regarding 
drug-drug interaction, metabolomics, gene expression, 
protein expression, diseases, drugs and, metabolomic 
flux etc. Directed arrows (edges) representing their 
respective databases for the information pool. the 
tool/ toolbox would integrate information parsed 
from Fluxome, Drugbank, mesH (ncbi), Proteome, 
transcriptome, metabolome and other databases to 
generate an optimal output. the output (prediction) 
could be used for clinical correlation and new targets 
identification in lab settings, which might regulate 
sc fates. this image was generated in cytoscape3.
Figure 2. a patient/ population data could act as an input for generating 
signature profile, which could be compared with the data 
available in repositories such as gene-expression profiles, 
snPs data, metabolomics data, proteomics data, sequencing 
data and imaging data. this data could be correlated with 
clinical data and treatments available using scs as a source. 
this system analysis may also include family history and 
demographics. the optimal solution will help in diagnosis/ 
prognosis of an individual, drug response, environmental 
response and the associated risks. the image was generated 
in cytoscape. the directed edges indicating the techniques/ 
procedure from which this data was generated. 
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development of a common tool available to public.       
In summary, a tool for integrated omics, drugs and clinical 
SC	data	analysis	will	 increase	 the	potential	of	SC	 to	 infinity	
and	hitherto	untreatable	diseases.	However,	extrapolation	of	in 
silico prediction to humans should not be considered without 
supporting pre-clinical/ clinical data and prior regulatory 
authority approval, which will otherwise undermine the 
beneficial	uses	of	this	tool.
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